MDS to Divest Proteomics Division
MDS wants to divest its Proteomics unit, and has begun looking for partners to take over the money-losing division, the company said today. “We believe that MDS Proteomics has value ... but that MDS Inc. cannot fund it over the long term,” Sharon Mathers, an MDS spokeswoman, told GenomeWeb today.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
